Life SciencesPharmaceuticalsTherapeutic AreaBehavioral Health

Major Depressive Disorder (MDD) - Epidemiology Forecast-2028

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $3,250 150 Pages DelveInsight February, 2020 DEL16145164
Lowest Prices Guaranteed
Price from $3,250
Length 150 Pages
Publisher DelveInsight
Published Date February, 2020
SKU DEL16145164

DelveInsight’s ‘Major Depressive Disorder (MDD)- Epidemiology Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of MDD in the 7 Major Markets (MM) i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017-2028
Major Depressive Disorder (MDD) - Disease Understanding
The DelveInsight Major Depressive Disorder epidemiology report gives the thorough understanding of the MDD by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Major Depressive Disorder in the 7 Major Markets (MM), i.e., United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. Major depressive disorder is the most prevalent and disabling form of depression. In addition to the immediate symptoms of depression, MDD results in poor quality of life overall, decreased productivity, and affects females more than males. MDD is one form of depressive illness, or mood disorder. Other forms include bipolar disorder (manic-depressive illness) and dysthymia.

Major Depressive Disorder (MDD) Epidemiology
The Major Depressive Disorder (MDD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major markets. The epidemiology data for Major Depressive Disorder epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Major Depressive Disorder Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (12 months prevalent cases of Major Depressive Disorder, age-specific cases of Major Depressive Disorder, gender-specific cases of Major Depressive Disorder, severity-specific cases of Major Depressive Disorder, treatable cases of Major Depressive Disorder, relapsed/refractory cases of Major Depressive Disorder) scenario of Major Depressive Disorder (MDD) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, total 12 months prevalent population of Major Depressive Disorder in 7 major markets was observed to be 34,011,712 cases in 2017.

Report Scope
• The report covers the descriptive overview of Major Depressive Disorder, explaining its causes and currently available therapies
• Comprehensive insight has been provided into the epidemiology of the Major Depressive Disorder and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan
• Additionally, an all-inclusive account of both the current and emerging therapies for Major Depressive Disorder are provided, along with assessment of the impact new therapies will have on the current treatment landscape
• A detailed review of global historical and forecasted Major Depressive Disorder market is included in the report, covering drug outreach in 7 MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Major Depressive Disorder market

Major Depressive Disorder Report Key Strengths

• 9 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake

Major Depressive Disorder Epidemiology Segmentation
• 12 months prevalent cases of Major Depressive Disorder
• Age-specific cases of Major Depressive Disorder in 7 MM
• Gender-specific cases of Major Depressive Disorder, in 7 MM
• Severity-specific cases of Major Depressive Disorder in 7 MM
• Treatable cases of Major Depressive in 7 MM
• Relapsed/refractory cases of Major Depressive Disorder in 7 MM


1. Key Insights
2. Disease Overview: Major Depressive Disorder (MDD)
2.1. Introduction
2.2. Sign and Symptoms
2.3. Types of Major Depressive Disorder
2.4. Causes of Major Depressive Disorder
2.5. Pathophysiology of Depression
2.6. Genetic Basis of Major Depressive Disorder
2.7. Biomarkers in MDD
2.8. Diagnosis and Severity
2.8.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. 7MM Total 12 Months Prevalent Patient Population of Major Depressive Disorder
4. Country Wise-Epidemiology of Major Depressive Disorder
4.1. United States
4.1.1. Assumptions and Rationale
4.1.2. 12 Months Prevalent Cases of Major Depressive Disorder in the United States
4.1.3. Age-Specific Cases of Major Depressive Disorder in the United States
4.1.4. Gender Specific Cases of Major Depressive Disorder in the United States
4.1.5. Severity Specific Cases of Major Depressive Disorder in the United States
4.1.6. Treatable Cases of Major Depressive Disorder in the United States
4.1.7. Relapse/Refractory Cases of Major Depressive Disorder in the United States
4.2. EU5
4.2.1. Assumptions and Rationale
4.3. Germany
4.3.1. 12 Months Prevalent Cases of Major Depressive Disorder in Germany
4.3.2. Age-Specific Cases of Major Depressive Disorder in Germany
4.3.3. Gender Specific Cases of Major Depressive Disorder in Germany
4.3.4. Severity Specific Cases of Major Depressive Disorder in Germany
4.3.5. Treatable Cases of Major Depressive Disorder in Germany
4.3.6. Relapse/Refractory Cases of Major Depressive Disorder in Germany
4.4. France
4.4.1. 12 Months Prevalent Cases of Major Depressive Disorder in France
4.4.2. Age-Specific Cases of Major Depressive Disorder in France
4.4.3. Gender Specific Cases of Major Depressive Disorder in France
4.4.4. Severity Specific Cases of Major Depressive Disorder in France
4.4.5. Treatable Cases of Major Depressive Disorder in France
4.4.6. Relapse/Refractory Cases of Major Depressive Disorder in France
4.5. Italy
4.5.1. 12 Months Prevalent Cases of Major Depressive Disorder in Italy
4.5.2. Age-Specific Cases of Major Depressive Disorder in Italy
4.5.3. Gender Specific Cases of Major Depressive Disorder in Italy
4.5.4. Severity Specific Cases of Major Depressive Disorder in Italy
4.5.5. Treatable Cases of Major Depressive Disorder in Italy
4.5.6. Relapse/Refractory Cases of Major Depressive Disorder in Italy
4.6. Spain
4.6.1. 12 Months Prevalent Cases of Major Depressive Disorder in Spain
4.6.2. Age-Specific Cases of Major Depressive Disorder in Spain
4.6.3. Gender Specific Cases of Major Depressive Disorder in Spain
4.6.4. Severity Specific Cases of Major Depressive Disorder in Spain
4.6.5. Treatable Cases of Major Depressive Disorder in Spain
4.6.6. Relapse/Refractory Cases of Major Depressive Disorder in Spain
4.7. United Kingdom
4.7.1. 12 Months Prevalent Cases of Major Depressive Disorder in the UK
4.7.2. Age-Specific Cases of Major Depressive Disorder in the UK
4.7.3. Gender Specific Cases of Major Depressive Disorder in the UK
4.7.4. Severity Specific Cases of Major Depressive Disorder in the UK
4.7.5. Treatable Cases of Major Depressive Disorder in the UK
4.7.6. Relapse/Refractory Cases of Major Depressive Disorder in the UK
4.8. Japan
4.8.1. Assumptions and Rationale
4.8.2. 12 Months Prevalent Cases of Major Depressive Disorder in Japan
4.8.3. Age-Specific Cases of Major Depressive Disorder in Japan
4.8.4. Gender Specific Cases of Major Depressive Disorder in Japan
4.8.5. Severity Specific Cases of Major Depressive Disorder in Japan
4.8.6. Treatable Cases of Major Depressive Disorder in Japan
4.8.7. Relapse/Refractory Cases of Major Depressive Disorder in Japan
5. Current Treatment Practices
5.1. American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder
5.2. Major Depressive Disorder Treatment Guidelines in the US and Europe
5.3. Guidelines in Spanish SHN for the Management of Major Depression in Adults
5.3.1. Therapeutic algorithm
5.4. Major Depressive Disorder Treatment Guidelines in Japan
5.5. Major depressive disorder –Clinical practice review
5.5.1. Treatment Options for Adults
5.5.2. Treatment Options for Children and Adolescents
5.5.3. Treatment Options for Late-Life (Older Adults)
5.6. Algorithm for the Management of Major Depressive Disorder
5.7. Algorithm for the Pharmacotherapy of MDD
6. Appendix
6.1. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
Table 1: DSM-IV-TR diagnostic criteria - MDD
Table 2: DSM-IV-TR diagnostic criteria for MDD, Single episode
Table 3: DSM-IV-TR diagnostic criteria for MDD, Recurrent
Table 4: Selected DSM-IV-TR Major Depressive Episode Specifier
Table 5: Major depressive disorder diagnostic criteria according to DSM-V
Table 6: General Diagnostic Criteria of a Depressive episode according to ICD-10
Table 7: Severity Criteria of a Depressive episode according to ICD-10
Table 8: 12 Months Prevalent Patient Population of MDD in the 7MM (2017–2028)
Table 9: 12 months Prevalent Cases of Major Depressive Disorder in the US (2017–2028)
Table 10: Age-Specific Cases of Major Depressive Disorder in the US (2017–2028)
Table 11: Gender Specific Cases of Major Depressive Disorder in the US (2017–2028)
Table 12: Severity Specific Cases of Major Depressive Disorder in the US (2017–2028)
Table 13: Treatable Cases of Major Depressive Disorder in the US (2017–2028)
Table 14: Relapse/Refractory Cases of Major Depressive Disorder in the US (2017–2028)
Table 15: 12 Months Prevalent Cases of Major Depressive Disorder in Germany (2017–2028)
Table 16: Age-Specific Cases of Major Depressive Disorder in Germany (2017–2028)
Table 17: Gender Specific Cases of Major Depressive Disorder in Germany (2017–2028)
Table 18: Severity Specific Cases of Major Depressive Disorder in Germany (2017–2028)
Table 19: Treatable Cases of Major Depressive Disorder in Germany (2017–2028)
Table 20: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2017–2028)
Table 21: 12 Months Prevalent Cases of Major Depressive Disorder in France (2017–2028)
Table 22: Age-Specific Cases of Major Depressive Disorder in France (2017–2028)
Table 23: Gender Specific Cases of Major Depressive Disorder in France (2017–2028)
Table 24: Severity Specific Cases of Major Depressive Disorder in France (2017–2028)
Table 25: Treatable Cases of Major Depressive Disorder in France (2017–2028)
Table 26: Relapse/Refractory Cases of Major Depressive Disorder in France (2017–2028)
Table 27: 12 Months Prevalent Cases of Major Depressive Disorder in Italy (2017–2028)
Table 28: Age-Specific Cases of Major Depressive Disorder in Italy (2017–2028)
Table 29: Gender Specific Cases of Major Depressive Disorder in Italy (2017–2028)
Table 30: Severity Specific Cases of Major Depressive Disorder in Italy (2017–2028)
Table 31: Treatable Cases of Major Depressive Disorder in Italy (2017–2028)
Table 32: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2017–2028)
Table 33: 12 Months Prevalent Cases of Major Depressive Disorder in Spain (2017–2028)
Table 34: Age-Specific Cases of Major Depressive Disorder in Spain (2017–2028)
Table 35: Gender Specific Cases of Major Depressive Disorder in Spain (2017–2028)
Table 36: Severity Specific Cases of Major Depressive Disorder in Spain (2017–2028)
Table 37: Treatable Cases of Major Depressive Disorder in Spain (2017–2028)
Table 38: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2017–2028)
Table 39: 12 Months Prevalent Cases of Major Depressive Disorder in the UK (2017–2028)
Table 40: Age-Specific Cases of Major Depressive Disorder in the UK (2017–2028)
Table 41: Gender Specific Cases of Major Depressive Disorder in the UK (2017–2028)
Table 42: Severity Specific Cases of Major Depressive Disorder in the UK (2017–2028)
Table 43: Treatable Cases of Major Depressive Disorder in the UK (2017–2028)
Table 44: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2017–2028)
Table 45: 12 Months Prevalent Cases of Major Depressive Disorder in Japan (2017–2028)
Table 46: Age-Specific Cases of Major Depressive Disorder in Japan (2017–2028)
Table 47: Gender Specific Cases of Major Depressive Disorder in Japan (2017–2028)
Table 48: Severity Specific Cases of Major Depressive Disorder in Japan (2017–2028)
Table 49: Treatable Cases of Major Depressive Disorder in Japan (2017–2028)
Table 50: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 1: : Structural and Functional Brain Abnormalities in Patients with Major Depressive Disorder
Figure 2: 12 Months Prevalent Patient Population of MDD in the 7MM (2017–2028)
Figure 3: 12 Months Prevalent Cases of Major Depressive Disorder in the US (2017–2028)
Figure 4: Age-Specific Cases of Major Depressive Disorder in the US (2017–2028)
Figure 5: Gender Specific Cases of Major Depressive Disorder in the US (2017–2028)
Figure 6: Severity Specific Cases of Major Depressive Disorder in the US (2017–2028)
Figure 7: Treatable Cases of Major Depressive Disorder in the US (2017–2028)
Figure 8: Relapse/Refractory Cases of Major Depressive Disorder in the US (2017–2028)
Figure 9: 12 Months Prevalent Cases of Major Depressive Disorder in Germany (2017–2028)
Figure 10: Age-Specific Cases of Major Depressive Disorder in Germany (2017–2028)
Figure 11: Gender Specific Cases of Major Depressive Disorder in Germany (2017–2028)
Figure 12: Severity Specific Cases of Major Depressive Disorder in Germany (2017–2028)
Figure 13: Treatable Cases of Major Depressive Disorder in Germany (2017–2028)
Figure 14: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2017–2028)
Figure 15: 12 Months Prevalent Cases of Major Depressive Disorder in France (2017–2028)
Figure 16: Age-Specific Cases of Major Depressive Disorder in France (2017–2028)
Figure 17: Gender Specific Cases of Major Depressive Disorder in France (2017–2028)
Figure 18: Severity Specific Cases of Major Depressive Disorder in France (2017–2028)
Figure 19: Treatable Cases of Major Depressive Disorder in France (2017–2028)
Figure 20: Relapse/Refractory Cases of Major Depressive Disorder in France (2017–2028)
Figure 21: 12 Months Prevalent Cases of Major Depressive Disorder in Italy (2017–2028)
Figure 22: Age-Specific Cases of Major Depressive Disorder in Italy (2017–2028)
Figure 23: Gender Specific Cases of Major Depressive Disorder in Italy (2017–2028)
Figure 24: Severity Specific Cases of Major Depressive Disorder in Italy (2017–2028)
Figure 25: Treatable Cases of Major Depressive Disorder in Italy (2017–2028)
Figure 26: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2017–2028)
Figure 27: 12 Months Prevalent Cases of Major Depressive Disorder in Spain (2017–2028)
Figure 28: Age-Specific Cases of Major Depressive Disorder in Spain (2017–2028)
Figure 29: Gender Specific Cases of Major Depressive Disorder in Spain (2017–2028)
Figure 30: Severity Specific Cases of Major Depressive Disorder in Spain (2017–2028)
Figure 31: Treatable Cases of Major Depressive Disorder in Spain (2017–2028)
Figure 32: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2017–2028)
Figure 33: 12 Months Prevalent Cases of Major Depressive Disorder in the UK (2017–2028)
Figure 34: Age-Specific Cases of Major Depressive Disorder in the UK (2017–2028)
Figure 35: Gender Specific Cases of Major Depressive Disorder in the UK (2017–2028)
Figure 36: Severity Specific Cases of Major Depressive Disorder in the UK (2017–2028)
Figure 37: Treatable Cases of Major Depressive Disorder in the UK (2017–2028)
Figure 38: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2017–2028)
Figure 39: 12 Months Prevalent Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 40: Age-Specific Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 41: Gender Specific Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 42: Severity Specific Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 43: Treatable Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 44: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2017–2028)
Figure 45: Basic Principles of Depression Treatment in American and European Guidelines
Figure 46: Japanese Treatment Algorithm for Mild-Moderate Major Depression
Figure 47: Unmet Needs for Major Depressive Disorder

$3,250
$9,750
 
Research assistance
US: 800.298.5699
Int'l: +1.240.747.3093
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks